Pharmanest AB introduced the first patient is dosed inside an open label pharmacokinetic survey having its drug candidate SHACT, a product created to relieve pain in reference to intrauterine device (IUD) insertion. Karolinska Development AB holds 55% of Pharmanest.
Pharmanest's Phase I-study is definitely an open study in the objective of building the pharmacokinetic features of SHACT when utilized within the cervix and uterus of women obtaining an IUD. Secondary aims are to assess the security and tolerability. A randomized, twice blind Phase II study by using about 200 affected individuals is deliberate to begin later in 2012.
Gunilla Lundmark, CEO of Pharmanest says that "Annually, countless females have IUDs inserted. Many women knowledge discomfort in reference to the insertion, and there are merely few local pain remedy products available on the market with recorded performance. Thus, in most countries, affected individuals have no variety except oral painkillers or no pain alleviation in any respect. We view a great necessity of local pain alleviation products in reference to IUD insertions and likewise in other gynecological steps".
No comments:
Post a Comment